Literature DB >> 1285304

Inhibitors of HIV-1 protease.

T D Meek1.   

Abstract

The human immunodeficiency virus (HIV), the etiological agent for the acquired immune deficiency syndrome (AIDS), is a retrovirus which makes use of a virally-encoded aspartic protease to perform specific proteolytic processing of two of its gene products in order to form active enzymes and structural proteins within the mature virion. Accordingly, specific, exogenous inhibition of the HIV-1 protease is thought to be a viable approach for the development of novel therapeutics for the treatment of AIDS. Indeed, this hypothesis has been validated in virally-infected cell culture with synthetic inhibitors of HIV-1 protease. This chapter reviews the current status of the development of inhibitors of this enzyme.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1285304     DOI: 10.3109/14756369209041357

Source DB:  PubMed          Journal:  J Enzyme Inhib        ISSN: 1026-5457


  9 in total

Review 1.  Combinatorial approaches to the prevention and treatment of HIV-1 infection.

Authors:  Vanessa Pirrone; Nina Thakkar; Jeffrey M Jacobson; Brian Wigdahl; Fred C Krebs
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

Review 2.  Mechanistic enzymology in drug discovery: a fresh perspective.

Authors:  Geoffrey A Holdgate; Thomas D Meek; Rachel L Grimley
Journal:  Nat Rev Drug Discov       Date:  2017-12-01       Impact factor: 84.694

3.  Bile pigments as HIV-1 protease inhibitors and their effects on HIV-1 viral maturation and infectivity in vitro.

Authors:  F McPhee; P S Caldera; G W Bemis; A F McDonagh; I D Kuntz; C S Craik
Journal:  Biochem J       Date:  1996-12-01       Impact factor: 3.857

4.  In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.

Authors:  S Kageyama; T Mimoto; Y Murakawa; M Nomizu; H Ford; T Shirasaka; S Gulnik; J Erickson; K Takada; H Hayashi
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

5.  Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease.

Authors:  A H Kaplan; S F Michael; R S Wehbie; M F Knigge; D A Paul; L Everitt; D J Kempf; D W Norbeck; J W Erickson; R Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

6.  Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.

Authors:  K Nagy; M Young; C Baboonian; J Merson; P Whittle; S Oroszlan
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

7.  Catalytic contribution of flap-substrate hydrogen bonds in "HIV-1 protease" explored by chemical synthesis.

Authors:  M Baca; S B Kent
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

8.  Urethane protected amino acid N-carboxyanhydrides and fluorides (U-NCAs and U2AAFs).

Authors:  M Wakselman; J P Mazaleyrat; J Savrda
Journal:  Amino Acids       Date:  1994-02       Impact factor: 3.520

9.  Construction of a molecular clone of ovine enzootic nasal tumor virus.

Authors:  Scott R Walsh; María Carla Rosales Gerpe; Sarah K Wootton
Journal:  Virol J       Date:  2016-12-30       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.